21:45 , Jul 13, 2017 |  BC Innovations  |  Targets & Mechanisms

Insider signaling

With evidence mounting that cell surface receptors keep signaling after they are internalized, a Takeda-backed study from Monash University has shown how the phenomenon could solve the riddle of why antagonists of the substance P...
19:17 , Jun 2, 2017 |  BC Week In Review  |  Company News

Appeals court reverses opinion, invalidates Aloxi palonosetron patents from Helsinn

In early May, a federal appeals court invalidated U.S. Patent Nos. 7,947,724; 7,947,725; 7,960,424; and 8,598,219 from Helsinn Healthcare S.A. (Lugano, Switzerland) covering Aloxi palonosetron. The decision allows competition from a generic palonosetron product from...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Company News

Helsinn, Eisai sales and marketing update

Helsinn and Eisai said the American Society of Clinical Oncology (ASCO) has recognized Akynzeo netupitant /palonosetron as an option to prevent acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy regimens. Helsinn...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Helsinn, Dr. Reddy’s Laboratories Ltd. deal

Helsinn and Dr. Reddy’s settled patent litigation for Aloxi palonosetron in the U.S. Dr. Reddy’s will now be able to market a generic version of Aloxi in the U.S. on Sept. 20, 2018, or earlier...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Company News

Helsinn, Chugai sales and marketing update

Chugai launched Akynzeo netupitant /palonosetron in the U.K. to prevent chemotherapy-induced nausea and vomiting (CINV). The cost of the fixed-dose combination of 300 mg netupitant, a neurokinin 1 (NK1) substance P receptor antagonist, and 0.5...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

The European Commission approved Akynzeo netupitant/palonosetron to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or moderately emetogenic cancer chemotherapy. The product is a fixed-dose combination of 300 mg...
07:00 , Jun 8, 2015 |  BC Week In Review  |  Clinical News

Aloxi palonosetron regulatory update

The European Commission approved an expanded label for Aloxi palonosetron from Helsinn to prevent chemotherapy-induced nausea and vomiting (CINV) to include pediatric patients ages >=1 month. The selective serotonin (5-HT3) receptor antagonist is now approved...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Akynzeo netupitant/palonosetron regulatory update

EMA’s CHMP recommended approval of Akynzeo netupitant/palonosetron (NEPA) from Helsinn to prevent acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy or with moderately emetogenic cancer chemotherapy. The product is a...
08:00 , Feb 23, 2015 |  BC Week In Review  |  Company News

Helsinn, Stendhal deal

Helsinn granted Stendhal exclusive rights to commercialize netupitant /palonosetron ( NEPA ) in Colombia, Ecuador, Mexico, Peru, Venezuela and undisclosed Central American countries. The product is a fixed-dose combination of 300 mg netupitant, a neurokinin...
08:00 , Feb 16, 2015 |  BC Week In Review  |  Company News

Helsinn, Mundipharma deal

Helsinn granted Mundipharma exclusive, Brazilian commercialization rights to NEPA . The fixed-dose combination of 300 mg netupitant , a neurokinin 1 (NK1) Substance P receptor antagonist, and 0.5 mg palonosetron, a selective serotonin (5-HT3) receptor...